These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7561238)

  • 1. Cytosolic tissue-type plasminogen activator (t-PA) levels in ductal infiltrating carcinomas of the breast classified according to different clinical and biological parameters.
    García Muñiz JL; Alvarez A; Fernández Llana B; Fernández Raigoso P; Allende MT; Ruibal A
    Int J Biol Markers; 1995; 10(2):119-21. PubMed ID: 7561238
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
    Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
    Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Infiltrating ductal carcinomas of the breast in women over 60 years of age. Association with higher cellular proliferation and lower PS2, cell surface and cytosolic hyaluronic acid concentrations].
    Ruibal A; Arias J; Del Río MC; Resino C; Tejerina A
    Rev Esp Med Nucl; 2001 Dec; 20(7):525-9. PubMed ID: 11709137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytosolic concentrations of cathepsin D in 88 infiltrating ductal breast carcinomas having negative estrogen and progesterone receptors. Correlation with other clinical and biological parameters].
    Ruibal A; Arias J; Lapeña G; García Díez S; Tejerina A
    Rev Esp Med Nucl; 2001 Jun; 20(4):332-3. PubMed ID: 11940423
    [No Abstract]   [Full Text] [Related]  

  • 5. [Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation].
    Ruibal A; Arias JI; Resino C; Lapeña G; Schneider J; Tejerina A
    Rev Esp Med Nucl; 2001 Aug; 20(5):365-8. PubMed ID: 11470070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of epidermal growth factor receptor (EGFR) in hormone-independent breast cancers].
    Ruibal A; Garrido-Pumar M; Arias JI
    Rev Esp Med Nucl; 2006; 25(1):15-9. PubMed ID: 16540006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
    Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
    Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical-biological characteristics of infiltrating ductal carcinomas of the breast with estrogen receptor concentrations >300 fmol/mg protein].
    Resino C; Arias JI; Del Río MC; Sánchez Hermosa C; Ruibal A
    Rev Esp Med Nucl; 2001 Oct; 20(6):503-5. PubMed ID: 11578586
    [No Abstract]   [Full Text] [Related]  

  • 9. Study of the expression on the CD44v5 adhesion molecule in invasive lobular carcinomas of the breast. Association between negativity and cellular S-phase fraction >7%.
    Ruibal A; Arias J; Del Rio MC; Schneider J; Tejerina A
    Int J Biol Markers; 2000; 15(2):195-6. PubMed ID: 10883896
    [No Abstract]   [Full Text] [Related]  

  • 10. [Preoperative serum CA15.3 and CEA levels and clinical-biological parameters in breast tumors].
    Ruibal A; Garrido Pumar M; Arias JI
    Rev Esp Med Nucl; 2006; 25(3):180-3. PubMed ID: 16762272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The cytosolic hyaluronic acid level defines several clinico-biological properties of CD44v5-positive infiltrating ductal carcinoma of the breast].
    Ruibal A; Arias JI; Carmen del Río M; San Román JM; Lapeña G; Schneider J; Tejerina A
    Med Clin (Barc); 2000 Jul; 115(6):201-7. PubMed ID: 11002457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinico-biological impact of pS2 positivity in estrogen receptor negative-infiltrating ductal carcinomas of the breast].
    Ruibal A; Arias J; del Río MC; San Román JM; Lapeña G; Pardo C; Tejerina A
    Rev Esp Med Nucl; 2000 Oct; 19(6):428-33. PubMed ID: 11060273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hormone-dependent, diploid, infiltrating ductal breast carcinomas less than 2 cm in size: influence of an exclusive and moderate cellular proliferation on the clinicobiological features and recurrences of these malignant tumors].
    Ruibal A; Arias JI
    Rev Esp Med Nucl; 2002; 21(6):437-8. PubMed ID: 12425893
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma.
    Göhring UJ; Scharl A; Thelen U; Ahr A; Crombach G
    Anticancer Res; 1996; 16(2):1011-8. PubMed ID: 8687092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cytosolic pS2 levels in 154 non-small-cell lung carcinomas. Correlation with other clinical and biological parameters].
    Ruibal A; Núñez MI; del Río MC; García Díez S; Rodríguez J; Alvarez De Linera JA
    Rev Esp Med Nucl; 2002 Apr; 21(2):109-14. PubMed ID: 11879619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical-biological differences between invasive ductal carcinomas and breast lobular carcinomas. Preliminary results].
    Ruibal A; Núñez MI; del Río Mf; Arias J; Martínez MI; Rabadán J; Tejerina A
    Rev Esp Med Nucl; 1999; 18(2):84-7. PubMed ID: 10352319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas.
    Hurlimann J; Gebhard S; Gomez F
    Histopathology; 1993 Sep; 23(3):239-48. PubMed ID: 8225242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytosolic tissue-type plasminogen activator (t-PA) levels in breast tumors and hormone dependence. Role of pS2.
    Ruibal A; Alvarez A; Fernández Llana B; Fernández Fernández M; Roiz MC; Allende MT
    Int J Biol Markers; 1994; 9(4):251-3. PubMed ID: 7836805
    [No Abstract]   [Full Text] [Related]  

  • 19. [Valoration of the epidermal growth factor receptor (EGFR) in benign breast disease and its relation with expression in malignant tumors classified by hormonal dependence].
    Allende MT; Raigoso PF; Alvarez A; Llana B; Sánchez A; Martínez MI; Miralles MT; Roiz C
    Rev Esp Med Nucl; 1999; 18(1):32-6. PubMed ID: 10074215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 as a prognostic factor in breast cancer.
    Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
    Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.